1. A Study on Portfolio Of Drugs Recommended for Neurological Disorders Saumya Agarwal Manipal Institute Of Management, Manipal 061203005

5. Stake Holders & Sample size Sample size =41 15 Doctors are seeing 60-70 patients per day. Range 30 to 70 patients per day 12 other company representatives

6. Disease Incidence 14% Others : Stoke (66%) for Neurologist and Mania, Anxiety, Alcoholism, De-addiction (34%)for Psychiatrist

7. Rx pattern for Epilepsy Divalproex / Sodium Valproate, Oxcarbazepine, Lamotrigine, Levitricitam, Clobazam emerge as “Drugs of choice “ in Generalised and Partial seizure , both as first line and second line

8. Launch Year:2002 Growth Rate:14.57% CAGR:41% Launch Year:2001 Growth Rate:20.11% CAGR:34% Launch Year:2005 Growth Rate:46.88% CAGR: Preferred Molecules Market Values

9. Launch Year:1998 Growth Rate:28.38% CAGR:34% Launch Year:1998 Growth Rate:16.52% CAGR:14% Preferred Molecules Market Values

11. Rx pattern for Alzheimer Citocholine & Donepezil emerged as the choice of drug in Alzheimer , while Donepezil and Memantamine preferred choice in step up and add on therapy.

12. Launch Year:2004 Growth Rate:80.51% CAGR: Launch Year:2001 Growth Rate:56.16% CAGR:34% Launch Year:2004 Growth Rate:10% CAGR: Preferred Molecules Market Values

13. Proposed New Formulations by Specialists Molecule Requirements From Doctor From Field Force Citocholine ER ,Inj 250 mg Inj 500 mg, Inj 1000 mg, 250 mg for stroke Donepezil ER Memantamine ER Proposed basket for Anti-Alzheimer drugs: Citocholine & Donepezil

15. Launch Year:2001 Growth Rate:15.74% CAGR:10% Launch Year:1997 Growth Rate:21.59% CAGR:12% Preferred Molecules Market Values

16. Launch Year:2002 Growth Rate:52.17% CAGR:16% Launch Year:1995 Growth Rate:9.09% CAGR:10%

17. Proposed New Formulations by Specialists Molecule Requirements From Doctor Form Field Force Quiteapine Risperidone Inj 2.5 mg, Inj 3 mg Inj Olanjapiene Oral sol 10 mg per day Olanjapene + Fluoxetine Combination Clojapiene Oral sol 10 mg per day Proposed Basket for Anti-Psychotic drugs: Quiteapine, Risperidone & Olanzapiene

19. Launch Year:2002 Growth Rate:14.57% CAGR:41% Launch Year:2000 Growth Rate:25% CAGR:25% Launch Year:1991 Growth Rate:3.07% CAGR:12% Preferred Molecules Market Values

20. Launch Year:2003 Growth Rate:130.77% CAGR:134% Launch Year:1996 Growth Rate:50% CAGR:6% Preferred Molecules Market Values

21. Since Rizatriptan is more effictive and safer than Sumatriptan and both belong to same family of Triptans ( Nasal Spray of Rizatriptan is a good option) Divalproex and Topiramate are being prescribed in both Epilepsy And Migraine Proposed basket for Migraine: Divalproex, Topiramate, Rizatriptan, And Funarizine Proposed New Formulations by Specialists Molecule Requirements From Doctor From Field Force Divalproex ER Tab 125 mg For children Topiramate Rizatriptan Flunarizine ER Sumatriptan Nasal Spray, ER

23. Launch Year:2007 Growth Rate:3600% CAGR: Launch Year:1999 Growth Rate:26.20% CAGR:13% Launch Year:1991 Growth Rate:0.00% CAGR:-20% Preferred Molecules Market Values

24. Proposed New Formulations by Specialists Molecule Requirements From Doctor From Field Force Zolpidem ER Eszopiclone ER Ramelton Flurazepam ER Proposed basket of molecules for Insomnia : Zolpidem, Eszopiclone, and Ramelton

26. Launch Year:2002 Growth Rate:14.61% CAGR:34% Launch Year:1998 Growth Rate:11.76% CAGR:6% Launch Year:2004 Growth Rate:1.97% CAGR: Preferred Molecules Market Values

27. Launch Year:1995 Growth Rate:15.46% CAGR:17% Launch Year:1990 Growth Rate:1.07% CAGR: 2% Preferred Molecules Market Values

28. Proposed New Formulations by Specialists Molecule Requirements From Doctor From Field Force Escitalopram ER / Oral Sols Escitalopram + Mirtazepam combination Duloxentine Clonazepam ER / Oral Sols Sertraline ER / Oral Sols Fluoxentine HCL ER / Inj ER Proposed basket for Depression : Escitalopram, Duloxentine & Clonazepam

29. Rx pattern for Parkinsonism Levo+carbi, Selegiline and Ropinirole are preferred over all in Parkinsonism

30. Launch Year:1990 Growth Rate:7.69% CAGR:1% Launch Year:1982 Growth Rate:18.14% CAGR:6% Launch Year:1987 Growth Rate:7.27% CAGR:11% Preferred Molecules Market Values

31. Launch Year:1991 Growth Rate:15% CAGR:-2% Launch Year:2001 Growth Rate:9.3% CAGR:11%

32. Proposed New Formulations by Specialists Molecule Requirements From Doctor From Field Force Levo + carbi Oral / Sols Amantidine Ropinirole Trihexphendyl Cl Selegeline Proposed basket of molecules for Parkinson: Levo + Carbi, Amantidine Ropinirole and Trihexphendyl Chloride

34. Proposed Portfolio of drugs for CNS Disease Molecule Epilepsy Divalproex, Clobazam Oxcarbazepine, Levitiracetam, Lamotrigine & Clobazam Alzheimer Citocholine & Donepezil Parkinson Levo + Carbi, Amantidine Ropinirole & Trihexphendyl Chloride Migraine Divalproex, Topiramate, Rizatriptan, & Funarizine Psychosis (Schizopherinia) Quiteapine, Risperidone & Olanzapiene Depression Escitalopram, Duloxentine & Clonazepam Insomnia Zolpidem, Eszopiclone, &Ramelton

35. Total CNS portfolio Specialty Diseases Neurologist Epilepsy, Parkinson Migraine, Insomnia, Depression Psychiatrist Epilepsy, Alzheimer, Psychosis, Parkinson Migraine, Insomnia, Depression General Physician Epilepsy, Migraine, Insomnia,Depression